securities class action

Rosen Law Firm urges Lakeland Industries investors to meet April 24, 2026 lead plaintiff deadline in securities class action alleging false statements about Pacific Helmets and Jolly businesses.

Rosen Law Firm urges $NKTR investors to join class action lawsuit alleging false statements about REZOLVE-AA trial enrollment protocols caused significant shareholder losses.

Investors in $PYPL who purchased stock between February 2025 and February 2026 may qualify for compensation in ongoing securities class action alleging false financial statements.

Rosen Law Firm launches securities class action against $TCOM for alleged material misstatements regarding regulatory risks and monopolistic practices. Lead plaintiff deadline: May 11, 2026.

Rosen Law Firm sues Atara Biotherapeutics for allegedly misrepresenting tabelecleucel drug's regulatory prospects and manufacturing capabilities to investors between May 2024 and January 2026. Lead plaintiff deadline set for May 22, 2026.

$POM investors have until April 7, 2026 to join class action alleging fraud involving fake promotions, insider trading, and market manipulation.

Rosen Law Firm filed securities lawsuit against $CWH, alleging material misstatements on inventory management and retail demand. Lead plaintiff deadline set for May 11, 2026.

Rosen Law Firm files class action against $LU over false statements regarding internal controls and financial reporting. Investors who purchased securities between April 2023 and January 2025 may be eligible.

ImmunityBio shares plunge 21% after FDA warning over unsupported cancer treatment claims, erasing $2 billion in market value and triggering securities litigation.

Rosen Law Firm urges monday.com investors to meet May 2026 deadline in securities fraud lawsuit alleging false growth claims.

Rosen Law Firm urges $PMI investors to join class action over alleged fraudulent stock promotion scheme involving social media misinformation and insider dumping.

Hagens Berman expands class action against Kyndryl (KD) for allegedly manipulating free cash flow metrics. Stock fell 55% after SEC probe; CFO and General Counsel departed.

Hagens Berman investigates $QURE over FDA allegations of misrepresented gene therapy data and manipulated study design. Stock tumbled 49% following November 3 FDA rebuttal.

Hagens Berman sues $CORT over alleged concealment of FDA warnings on relacorilant. Stock crashed 50% following Complete Response Letter, erasing $2.5B in market value.

Navan faces securities lawsuit over allegedly omitted $95M sales expense surge in IPO documents; stock down 63% from $25 offering price.

Trip.com shares crashed 17% after Chinese regulators launched anti-monopoly probe into allegedly coercive AI pricing tool. Securities lawsuit filed.

Rosen Law Firm files securities class action against $ALIT for allegedly misrepresenting growth potential and financial stability. Investors have until May 15, 2026 to claim lead plaintiff status.

The Gross Law Firm filed a class action lawsuit against uniQure N.V. for allegedly making false statements about FDA approval and BLA timeline prospects.

Rosen Law Firm filed a securities class action against Kyndryl Holdings alleging false disclosures on financials and internal controls, with an April 2026 lead plaintiff deadline.

Rosen Law Firm files class action against Richtech Robotics ($RR) for allegedly misrepresenting Microsoft collaboration. Investors have until April 3 to join suit.